Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guerin Instillations: The EAU-RF NIMBUS Trial.

ABSTRACT:

Background

Adverse events induced by intravesical bacillus Calmette-Guérin (BCG) to treat high-grade non-muscle-invasive bladder cancer (NMIBC) often lead to treatment discontinuation. The EAU-RF NIMBUS trial found a reduced number of standard-dose BCG instillations to be inferior with the standard regimen. Nonetheless, it remains important to evaluate whether patients in the reduced BCG treatment arm had better quality of life (QoL) due to a possible reduction in toxicity or burden.

Objective

To evaluate whether patients in the EAU-RF NIMBUS trial experienced better QoL after a reduced BCG instillation frequency.

Design setting and participants

A total of 359 patients from 51 European sites were randomized to one of two treatment arms between December 2013 and July 2

SUBMITTER: van Straten CGJI 

PROVIDER: S-EPMC10562176 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature